About: Scioderm

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Scioderm Goto Sponge NotDistinct Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FScioderm&invfp=IFP_OFF&sas=SAME_AS_OFF

Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.

Attributes	Values
rdf:type	Thing company schema:Organization dul:Agent dul:SocialPerson agent wikidata:Q24229398 Organization Business enterprise organisation
rdfs:label	Scioderm (en)
rdfs:comment	Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions. (en)
foaf:name	Scioderm (en)
foaf:homepage	http://sderm.com
name	Scioderm (en)
dcterms:subject	Drug discovery companies Breakthrough therapy Pharmaceutical companies of the United States Technology companies established in 2012 Orphan drug companies
Wikipage page ID	47655347 (xsd:integer)
Wikipage revision ID	965023954 (xsd:integer)
Link from a Wikipage to another Wikipage	Drug discovery companies DEBRA University of Minnesota Morgenthaler Pharmaceutical industry Amicus Therapeutics Durham, North Carolina European Medicines Agency Food and Drug Administration Breakthrough therapy Epidermolysis Bullosa Breakthrough therapy Pharmaceutical companies of the United States Technology companies established in 2012 Orphan drug companies Breakthrough Therapy Orphan Drug Connective tissue disorder
sameAs	Scioderm Scioderm Scioderm
dbp:wikiPageUsesTemplate	dbt:COI dbt:Infobox_company dbt:Official_website dbt:Reflist dbt:Start_date dbt:Use_dmy_dates
brands	Zorblisa (en)
founders	Robert Coull, CA, CBV (en) Robert Ryan, Ph.D. (en)
hq location city	Durham, North Carolina
industry	Pharmaceutical industry
products	SD-101 for epidermolysis bullosa (en)
has abstract	Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions. Epidermolysis Bullosa, sometimes referred to as "Butterfly Skin", is a rare genetic connective tissue disorder that, in all forms, results in extremely fragile skin that blisters or tears at the slightest friction or trauma. EB typically manifests at birth or early childhood. According to the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA), an estimated 1 out of every 20,000 live births are affected with some type of EB and the disorder occurs in every racial and ethnic group throughout the world and affects both sexes equally. In Scioderm's initial open-label Phase 2 study conducted in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB, the application of SD-101 resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in Body Surface Area (BSA) coverage of lesions and erosions after 3 months of daily treatment. SD-101, now owned by Amicus Therapeutics, is currently in Phase 3 clinical development to evaluate Zorblisa as a therapy for the treatment of lesions and blistering associated with Epidermolysis Bullosa. Zorblisa is the first drug to ever enter Phase 3 development for the treatment of EB. Stem cell research for Epidermolysis Bullosa is also underway by researchers at the University of Minnesota pursuant to an open-label Phase 2 trial. In April 2013 Scioderm received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its topical treatment, SD-101 for Epidermolysis Bullosa. As a result of receiving Breakthrough therapy designation for SD-101, Scioderm was named a 2013 "Fierce Top 15" company by FierceBiotech. Prior to Scioderm's receipt of the FDA's Breakthrough therapy designation for SD-101, it had only been given to high-profile pharmaceutical companies such as Johnson & Johnson, Merck and Novartis. In addition to Breakthrough therapy designation, Scioderm received Orphan Drug Designation from both the FDA and from the European Medicines Agency (EMA) for its EB treatment. (en)
gold:hypernym	Company
prov:wasDerivedFrom	wikipedia-en:Scioderm?oldid=965023954&ns=0
page length (characters) of wiki page	9206 (xsd:nonNegativeInteger)
industry	Pharmaceutical industry
location city	Durham, North Carolina
foaf:isPrimaryTopicOf	wikipedia-en:Scioderm
is Link from a Wikipage to another Wikipage of	Amicus Therapeutics
is foaf:primaryTopic of	wikipedia-en:Scioderm

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software